Results 21 to 30 of about 22,830 (226)

Detection of ROS1 gene fusions using next-generation sequencing for patients with malignancy in China

Frontiers in Cell and Developmental Biology, 2022
Objective: This study aimed to identify ROS1 fusion partners in Chinese patients with solid tumors.Methods: Next-generation sequencing (NGS) analysis was used to detect ROS1 rearrangement in 45,438 Chinese patients with solid tumors between 2015 and 2020,
Ning Li, Zhiqin Chen, Mei Huang, Ding Zhang, Mengna Hu, Feng Jiao, Ming Quan   +6 more
doaj   +1 more source

Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins [PDF]

Journal of Thoracic Oncology, 2018
The identification of key oncogenic driver alterations in NSCLC has led to the development of tailored treatments. ROS1 rearrangements occur in 1% to 2% of NSCLC.1 Dysregulation of MNNG HOS Transforming gene (MET) signaling through MET exon 14 skipping mutations or MET amplification has been reported in 3% to 4% and 2% to 5% of adenocarcinomas ...
Rihawi K, Cinausero M, Fiorentino M, SALVAGNI, SANDRO, Brocchi S, Ardizzoni A   +5 more
openaire   +2 more sources

Tester for deteksjon av ROS1 genforandringer blant pasienter med ikke små-cellet lungekreft: en forenklet metodevurdering. [PDF]

, 2021
Key messages: The Norwegian Institute of Public Health has been commissioned to evaluate molecular tests for the identification of somatic ROS1 gene alterations in people with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Hamidi Ashtiani, Vida, Flodgren, Gerd Monika   +1 more
core   +2 more sources

ROS1 in non-small-cell lung carcinoma: A narrative review

Cancer Research, Statistics, and Treatment, 2022
ROS1 rearranged non-small-cell lung cancer (NSCLC) is a distinct molecular subtype of NSCLC, accounting for 2% of cases. Typically, these are genomic rearrangements resulting in a fusion oncoprotein that causes unabated constitutive signaling.
Shrinidhi Nathany, Ullas Batra, Rashi Sachdeva, Mansi Sharma, B P Amrith, Shriya Vaidya   +5 more
doaj   +1 more source

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers [PDF]

Modern Pathology, 2014
The recent discovery and characterization of an oncogenic ROS1 gene fusion in a subset of lung cancers has raised significant clinical interest because small molecule inhibitors may be effective to these tumors. As lung cancers with ROS1 rearrangements comprise only 1-3% of lung adenocarcinomas, patients with such tumors must be identified to gain ...
Akihiko, Yoshida, Koji, Tsuta, Susumu, Wakai, Yasuhito, Arai, Hisao, Asamura, Tatsuhiro, Shibata, Koh, Furuta, Takashi, Kohno, Ryoji, Kushima   +8 more
openaire   +2 more sources

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing

BMC Cancer, 2023
Background Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. We performed a pan-tumor analysis of the incidence of ROS1 fusions to assess if more ROS1+ patients who could ...
Misako Nagasaka, Shannon S. Zhang, Yasmine Baca, Joanne Xiu, Jorge Nieva, Ari Vanderwalde, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Luis E. Raez, Stephen V. Liu, Sai-Hong Ignatius Ou   +11 more
doaj   +1 more source

Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors [PDF]

Modern Pathology, 2015
Inflammatory myofibroblastic tumor is a distinctive, rarely metastasizing mesenchymal neoplasm composed of fascicles of spindle cells with a prominent inflammatory infiltrate. Roughly 50% of inflammatory myofibroblastic tumors harbor ALK receptor tyrosine kinase gene rearrangements. Such tumors are usually positive for ALK by immunohistochemistry.
Jason L, Hornick, Lynette M, Sholl, Paola, Dal Cin, Merrida A, Childress, Christine M, Lovly   +4 more
openaire   +2 more sources

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer

Frontiers in Immunology, 2020
The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable.
Liangliang Cai, Liangliang Cai, Liangliang Cai, Jianchun Duan, Li Qian, Li Qian, Zhijie Wang, Shuhang Wang, Sini Li, Chao Wang, Jie Zhao, Xue Zhang, Hua Bai, Jie Wang   +13 more
doaj   +1 more source

Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. [PDF]

PLoS ONE, 2014
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotinib. We investigated the usefulness of ROS1 immunohistochemistry (IHC) for the detection of patients who harbor ROS1 rearrangements in two separate cohorts.
Yoon Jin Cha, Jae Seok Lee, Hye Ryun Kim, Sun Min Lim, Byoung Chul Cho, Chang Young Lee, Hyo Sup Shim   +6 more
doaj   +1 more source

Assessment of ROS1 Gene Rearrangement in Non-Small Cell Lung Cancer: Concordance Between ROS1 SP384 Immunohistochemistry and ROS1 FISH Assay in a Single Center in Türkiye [PDF]

Türk Patoloji Dergisi
Objective: Lung cancer is the most prevalent malignancy among men and women in Türkiye. National guidelines have been established to standardize molecular pathology diagnoses for the detection of driver mutations in non-small cell lung cancer with impact
Claudia Andrea GÓMEZ GONZÁLEZ, Gurdeniz SERIN, Pinar GURSOY, Ali VERAL, Deniz NART   +4 more
doaj   +1 more source